Actelion Ltd (ATLN.VX) is nominating two pharmaceutical industry veterans to join its board as it ramps up efforts to get shareholders onside ahead of what is likely to be a tense annual general meeting on May 5. The Swiss biotech group has come under fire from largest shareholder Elliott Advisors for eroding shareholder value and the New York-based fund has urged Actelion to consider putting itself up for sale after a spate of product setbacks last year. Elliott, which holds nearly 6 percent of the $7 billion group, has also proposed six new board members to the Actelion board and called for chief executive Jean-Paul Clozel and chairman Robert Cawthorn to step down from the board.
Source
